Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore

News

Stay up to date on the latest crypto trends with our expert, in-depth coverage.

banner
Flash
20:53
According to the latest filing with the U.S. Securities and Exchange Commission (SEC), Caris Life Sciences Inc has reached a comprehensive credit agreement.
The agreement consists of three core financing arrangements: a $400 million term loan, a $300 million delayed draw loan, and an incremental financing facility of up to $500 million. This credit arrangement significantly enhances the company’s financial flexibility. The term loan provides immediate funding support, the delayed draw mechanism allows the company to access funds in phases based on future needs, and the incremental financing facility reserves ample room for potential strategic expansion. This financing move provides Caris Life Sciences with robust funding support for subsequent R&D investments and business expansion.
20:53
According to the latest filing with the U.S. Securities and Exchange Commission (SEC), the biopharmaceutical company Immunic, Inc. has initiated an equity resale program.
The plan allows selling shareholders to register and resell up to 458.2 million shares of common stock. This stock registration aims to provide liquidity for existing shareholders while expanding the company's participation in the capital markets. If all the shares are resold, it may have a certain impact on the company's equity structure. The market will closely monitor subsequent developments to assess the potential impact on the stock price.
News